# Filana Therapeutics Appoints Jill Quigley to Board

> Filana Therapeutics adds Jill Quigley to its board ahead of simufilam Phase 2a study in TSC-related epilepsy.
- Title: Filana Therapeutics Appoints Jill Quigley to Board · Pulse 2.0
- Summary: Filana Therapeutics adds Jill Quigley to its board ahead of simufilam Phase 2a study in TSC-related epilepsy. Filana Therapeutics appointed Jill M.
- Keywords: filana therapeutics, jill quigley, simufilam, phase 2a study, tuberous sclerosis complex, epilepsy, clinical trial, independent director, board appointment, biotechnology, Pulse 2.0
- Source: Pulse 2.0 — https://pulse2.com/filana-therapeutics-jill-quigley-joins-board-ahead-of-simufilam-phase-2a-study
- Author: Amit Chowdhry
- Published: 2026-11-13T18:47:14+00:00
- Read time: 1 min
- Topics: filana therapeutics, jill quigley, simufilam, phase 2a study, tuberous sclerosis complex, epilepsy, clinical trial, independent director, board appointment, biotechnology, startups, business
## Filana Appoints Jill Quigley
Filana Therapeutics appointed Jill M. Quigley as independent director with over 20 years of biotech experience.
## Simufilam for TSC Epilepsy
Filana develops simufilam to treat epilepsy associated with tuberous sclerosis complex.
## Tuberous Sclerosis Complex
Tuberous sclerosis complex causes noncancerous tumors in multiple organs including the brain.
## Phase 2a Study Timeline
Filana expects patient screening for simufilam study to begin by first quarter of 2027.
## Jill Quigley's Background
Quigley served as CEO of a preclinical biotech company since November 2026.
## Board Expertise for Clinical Development
Quigley's experience helps Filana oversee clinical strategy and capital requirements for simufilam study.
## Key takeaway

Filana Therapeutics appointed Jill M. Quigley as independent director to support its simufilam Phase 2a clinical study for TSC-related epilepsy starting in Q1 2027.